Who are Miltefosine plus GM-CSF's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/miltefosine-plus-gm-csf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Miltefosine plus GM-CSF — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Miltefosine plus GM-CSF (Miltefosine plus GM-CSF) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic immunotherapy combination. Area: Infectious Disease / Parasitology.

phase 3 Antiparasitic immunotherapy combination Leishmania cell membrane; GM-CSF receptor Infectious Disease / Parasitology Small molecule Live · refreshed every 30 min

Target snapshot

Miltefosine plus GM-CSF (Miltefosine plus GM-CSF) — Hospital Universitário Professor Edgard Santos. Miltefosine combined with GM-CSF works by inducing immunogenic cell death and enhancing immune activation to treat leishmaniasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Miltefosine plus GM-CSF TARGET	Miltefosine plus GM-CSF	Hospital Universitário Professor Edgard Santos	phase 3	Antiparasitic immunotherapy combination	Leishmania cell membrane; GM-CSF receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic immunotherapy combination class)

Hospital Universitário Professor Edgard Santos · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Miltefosine plus GM-CSF — Competitive Intelligence Brief. https://druglandscape.com/ci/miltefosine-plus-gm-csf. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing